Targeted therapy is one of the most burgeoning areas of development in cancer research. Increasing knowledge in tumor formation and growth at the molecular level has generated a broad array of therapeutic options, including signal transduction inhibition, anti-angiogenic and anti-vascular agents, cell cycle inhibitors, telomerase and telomere interacting agents, apoptosis inducers, and anti-invasive agents.

This book presents an authoritative overview of existing molecular targeted therapies, their relevance and role for specific tumors, and their clinical efficacy and impact on patient treatment.

Key Features:

• Responding to the expanding array of targeted agents currently under clinical development, covers a broad array of innovative anticancer agents with a well-defined molecular target, including the most promising ones in preclinical and clinical development
• Supplies a current overview of the different therapeutic classes of existing targeted agents and explains their relevance and impact upon specific tumors
• Contains the most recent findings regarding the clinical activity and therapeutic spectrum of targeted compounds
• Analyzes the response rates, stabilization, and clinical benefits of specific molecular targeting
• Identifies research pathways that may impact the future of cancer therapy, as well as an expert discussion of recent clinical trial results